The company has established R&D centers in Beijing and Guangzhou, focusing on the research and development of high-end dosage forms such as long-acting preparations, controlled-release preparations and targeted nano-preparations.

Up to now, it has participated in the development of more than 20 marketed products and over 10 clinical-stage products, covering all dosage forms of drugs for cardiovascular and cerebrovascular diseases, neuroinhibition, immunosuppression, tumor targeting and other therapeutic areas.